Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)

Author:

Maluf Fernando Cotait123ORCID,Pereira Felipe Moraes Toledo34ORCID,Serrano Uson Pedro Luiz1,Bastos Diogo Assed356ORCID,Rodrigues da Rosa Diogo Augusto37,Wiermann Evanius Garcia38,Schutz Fábio A.23,Kater Fábio Roberto23,de Oliveira Fernando Nunes Galvão39,Marques Monteiro Fernando Sabino31011ORCID,de Pádua Fernando Vidigal312,Orlandi Francisco Javier13,de Almeida Saito Helena Paes14,Ayadi Mouna1516,Boghikian Pamela Salman17,Kopp Ray Manneh31819ORCID,de Carvalho Ricardo Saraiva23,de Fogace Rodrigo Nogueira13,de Araújo Cavallero Sandro Roberto20ORCID,Aguiar Sergio21,Souza Vinicius Carreira322,Sommer Silke Gillessen2324ORCID

Affiliation:

1. Hospital Israelita Albert Einstein, São Paulo, Brazil

2. Beneficência Portuguesa de São Paulo, São Paulo, Brazil

3. Latin American Oncology Group (LACOG), Rio Grande do Sul, Brazil

4. Hospital São Camilo, São Paulo, Brazil

5. Hospital Sirio-Libanês, São Paulo, Brazil

6. Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil

7. Grupo Oncoclínicas, Rio de Janeiro, Brazil

8. Instituto de Oncologia do Paraná, Curitiba, Brazil

9. Clinica CLION/Grupo CAM, Salvador, Bahia

10. Hospital Santa Lucia, Brasília, Brazil

11. Hospital Universitário de Brasília, Brasília, Brazil

12. Hospital Sírio Libanês, Brasília, Brazil

13. Orlandi Oncología, Santiago, Chile

14. Centro de Oncologia Campinas, São Paulo, Brazil

15. Institut Salah-Azaïz de Cancerologie, Tunis

16. Faculté de Médecine, Tunis, Tunisia

17. Fundacion Arturo Lopez Perez, Santiago, Chile

18. Clínica Porto Azul, Barranquilla, Colombia

19. Hospital Universitario 12 de Octubre, Madrid, Spain

20. Hospital Ophir Loyol, Belém, Pará, Brazil

21. Universidad de la República, Montevideo, Uruguay

22. Grupo de oncologia D'Or, Rio de Janeiro, Brazil

23. Oncology Institute of Southern Switzerland (IOSI), Bellinzona and Università della Svizzera Italiana, Lugano, Switzerland

24. Manchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

Abstract

PURPOSE International guideline recommendations may not always be extrapolated to developing countries where access to resources is limited. In metastatic castration-sensitive prostate cancer (mCSPC), there have been successful drug and imaging advancements that were addressed in the Prostate Cancer Consensus Conference for Developing Countries for best-practice and limited-resource scenarios. METHODS A total of 24 out of 300 questions addressed staging, treatment, and follow-up for patients with mCSPC both in best-practice settings and resource-limited settings. Responses were compiled and presented in percentage of clinicians supporting each response. Questions had 4-8 options for response. RESULTS Recommendations for staging in mCSPC were split but there was consensus that chest x-ray, abdominal and pelvic computed tomography, and bone scan should be used where resources are limited. In both de novo and relapsed low-volume mCSPC, orchiectomy alone in limited resources was favored and in relapsed high-volume disease, androgen deprivation therapy plus docetaxel in limited resources and androgen deprivation therapy plus abiraterone in high-resource settings were consensus. A 3-weekly regimen of docetaxel was consensus among voters. When using abiraterone, a regimen of 1,000 mg plus prednisone 5 mg/d is optimal, but in limited-resource settings, half the panel agreed that abiraterone 250 mg with fatty foods plus prednisone 5 mg/d is acceptable. The panel recommended against the use of osteoclast-targeted therapy to prevent osseous complications. There was consensus that monitoring of patients undergoing systemic treatment should only be conducted in case of prostate-specific antigen elevation or progression-suggestive symptoms. CONCLUSION The treatment recommendations for most topics addressed differed between the best-practice setting and resource-limited setting, accentuating the need for high-quality evidence that contemplates the effect of limited resources on the management of mCSPC.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3